Improvement of the ocular bioavailability of timolol by sorbic acid

International Journal of Pharmaceutics

Volumn 272, Issue 1-2, 2004, Pages 91-98

  Higashiyama, Masayo ^a   Inada, Katsuhiro ^a   Ohtori, Akira ^a   Tojo, Kakuji ^b  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Bilayer diffusion model; Ion pair; Ocular bioavailability; Ophthalmic solution; Timolol maleate

Indexed keywords

OCTANOL; SORBIC ACID; TIMOLOL; TIMOLOL MALEATE; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA PERMEABILITY; DIFFUSION COEFFICIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; LIPOPHILICITY; MALE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RABBIT;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; EXCIPIENTS; GELS; MALE; MODELS, BIOLOGICAL; OCTANOLS; OPHTHALMIC SOLUTIONS; PERMEABILITY; RABBITS; SORBIC ACID; TIME FACTORS; TIMOLOL; WATER;

EID: 1442348828     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.11.035     Document Type: Article

References (24)

1. Ash, M., Ash, I., 2002. Pharmaceutical Additives, Electronic Handbook, 2nd ed. Synapse Information Resources, Inc., New York.
2. Akafo S.K., Thompson J.R., Rosenthal A.R. A cross-over trial comparing once daily levobunolol with once and twice daily timolol. Eur. J. Ophthalmol. 5:1995;172-176.
3. Chien D.S., Bundgaard H., Lee V.H.L. Influence of corneal epithelial integrity on the penetration of timolol prodrugs. J. Ocul. Pharmacol. 4:1988;137-146.
4. DeSantis Jr., L.M., Patil, P.N., 1994. Pharmacokinetics. In: Mauger, T.F., Craig, E.L. (Eds.), Havener's Ocular Pharmacology, 6th ed. Mosby-Year Book, Mosby, MO, pp. 22-52.
5. El-Kamel A.H. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241:2002;47-55.
6. Friedrich S.W., Saville B.A., Cheng Y.L., Rootman D.S. Pharmacokinetic differences between ocular inserts and eyedrops. J. Ocul. Pharmacol. Ther. 12:1996;5-18.
7. Gallarate M., Gasco M.R., Trotta M. Influence of octanoic acid on membrane permeability of timolol from solutions and from microemulsions. Acta Pharm. Technol. 34:1988;102-105.
8. Gasco M.R., Gallarate M., Trotta M., Bauchiero L., Gremmo E., Chiappero O. Microemulsions as topical delivery vehicles: ocular administration of timolol. J. Pharm. Biomed. Anal. 7:1989;433-439.
9. Huang H.S., Schoenwald R.D., Lach J.L. Corneal penetration behavior of β-blocking agent. II. Assessment of barrier contributions. J. Pharm. Sci. 72:1983;1272-1279.
10. Japanese Pharmaceutical Excipients Directory, 2000. Japan Pharmaceutical Excipients Council (Ed.). Yakuji Nippo, Ltd., Tokyo, Japan, p. 161 (in Japanese).
11. Kato A., Iwata S. In vitro study on corneal permeability to bunazosin. J. Pharmacobiodyn. 11. 1988;115-120.
12. Lee V.H.L. Mechanisms and facilitation of corneal drug penetration. J. Control. Release. 11:1990;79-90.
13. Martin, A., 1993. Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, 4th ed. Lea & Febiger, London (Chapter 19), pp. 538-545.
14. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthal. Surg. 26:1995;233-236.
15. ®: a novel, ion-activated, in situ gelling polymer for opthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm. 57:1989;163-168.
16. Sasaki H., Nagano T., Yamamura K., Nishida K., Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J. Pharm. Pharmacol. 47:1995a;703-707.
17. Sasaki H., Igarashi Y., Nagano T., Nishida K., Nakamura J. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm. Res. 12:1995b;1146-1150.
18. Sasaki H., Igarashi Y., Nagano T., Yamamura K., Nishida K., Nakamura J. Penetration of β-blockers through ocular membranes in albino rabbits. J. Pharm. Pharmacol. 47:1995c;17-21.
19. Shedden A.H. Timolol maleate in gel-forming solution: a novel formulation of timolol maleate. Chibret Int. J. Ophthalmol. 10:1994;32-36.
20. Shields, M.B., 1992. Adrenergic inhibitors. In: Textbook of Glaucoma, 3rd ed. Williams & Wilkins, Maryland, pp. 480-499.
21. Tojo K., Chiang C.C., Chien Y.W. Drug permeation across the skin: effect of penetrant hydrophilicity. J. Pharm. Sci. 76:1987;123-126.
22. Vandamme T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye Res. 21:2002;15-34.
23. Wada T., Nagoshi K., Tahira N., Sugiyama M., Toyoda Y., Takeuchi M., Oguma T., Ezure Y. WP-934: developed reversible thermo-setting, in situ gelling ophthalmic solution. I. Timolol concentrations in ocular tissues and plasma after single instillation in the eyes of albino rabbits. Atarashii Ganka (J. Eye). 16:1999a;1013-1018.
24. ® TG). Atarashii Ganka (J. Eye). 16:1999b;1311-1314.